What each technique actually does to the damaged hip joint

The two procedures start from the same surgical decision — that a patch of damaged hip cartilage will not recover on its own and needs active help. Hip articular cartilage has no meaningful self-repair capacity; focal chondral defects caused by trauma, femoroacetabular impingement (FAI), labral injury, or osteonecrosis tend to worsen over time rather than stabilise.

Microfracture addresses this by creating small perforations in the bone just beneath the defect — the subchondral layer — to release a controlled bleed of marrow stem cells. These cells form a clot that fills the cavity and matures into repair tissue. The problem lies in what that tissue actually is: predominantly type I collagen, the same fibrous material found in ordinary scar. This fibrocartilage lacks the shock-absorbing and load-distributing properties of native hyaline cartilage, which is built from type II collagen.

AMIC — autologous matrix-induced chondrogenesis, first described by Behrens et al. — takes the same first step. The surgeon performs the bone perforation exactly as in microfracture, then immediately lays a resorbable bilayer collagen I/III membrane (Chondro-Gide, Geistlich Pharma) over the prepared defect. The scaffold holds the fragile marrow clot in place, keeps stem cells localised within the repair zone, and shields the maturing tissue from the shear forces the hip generates under load. That protected environment guides the repair toward hyaline-like tissue — richer in type II collagen — rather than fibrocartilage scar.

Both procedures are performed arthroscopically within the hip joint. AMIC adds operating time and a scaffold, but not a different surgical platform or approach.

Why microfracture fails in the hip over time

Microfracture has a meaningful track record for small focal defects — for many years it was the first-line procedure precisely because it is straightforward and reliably produces short-term symptom relief. The difficulty is what happens between 18 and 36 months.

The fibrocartilage tissue microfracture generates lacks the architecture the hip joint specifically demands. Native hyaline cartilage distributes load across the femoral head and acetabulum through a sophisticated matrix; fibrocartilage cannot replicate that and is vulnerable to the compressive and shear forces a functioning hip generates with every step. Over time the repair tissue breaks down rather than remodels.

The data on this deterioration are consistent. Kreuz et al. documented significant decreases in clinical outcome scores between 18 and 36 months after marrow-stimulation procedures — a window that maps closely to when patients and surgeons begin to notice renewed symptoms. Solheim et al. reported survivorship below 60% at three years, with a mean time to failure of approximately four years. In the wider hip literature, failure rates of around 62% at four years have been cited, confirming that short-term relief does not translate to durable benefit for most patients.

The hip joint adds a specific complication that other joints do not share. Its enclosed, spherical anatomy and relatively large joint volume make early clot stabilisation harder — the fragile marrow clot that microfracture depends on is more readily displaced before it can consolidate. That mechanical vulnerability compounds the underlying problem of repair-tissue quality.

For very small, strictly focal defects in otherwise well-preserved hips, microfracture may still have a role. For larger lesions or patients where long-term joint preservation is the objective, the two-year deterioration pattern is the decisive limitation.

How the AMIC scaffold changes the repair environment

The reason this scaffolded environment produces more durable repair lies in how Chondro-Gide is constructed. Its bilayer design — a porous inner surface encouraging stem-cell attachment and ingrowth, paired with a denser outer layer limiting fluid intrusion from the joint space — acts less like a patch and more like a mould: the biological material from the marrow response is already present, but the scaffold gives it a three-dimensional framework to set within. Without that containment, the clot can shift or disperse in the enclosed hip joint before consolidation begins.

The membrane gradually disappears as the new tissue matures, resorbing over approximately four months. No second procedure is needed to remove it.

The Gille AMIC Registry offers early clinical evidence for what this mechanism achieves. Fifty-seven patients — mean age 37.3 years, mean defect size 3.4 cm² — showed significant reductions in VAS pain (p<0.001) and meaningful functional improvement at both one and two years post-operatively. That defect size is relevant: at 3.4 cm² these patients fall well beyond the range where microfracture would be expected to hold, yet outcomes remained stable across both follow-up points.

The repair tissue produced is described throughout the literature as hyaline-like rather than true hyaline cartilage — a distinction worth maintaining. It contains a higher proportion of type II collagen than fibrocartilage, improving its load-bearing characteristics, but it should not be equated with the original articular surface that was lost.

Which hip patients are suited to each procedure

Candidacy for either procedure depends on three overlapping factors: lesion size, the underlying cause of the damage, and the overall condition of the joint.

Lesion size is the most immediate filter. Microfracture remains a reasonable option for small, strictly focal defects below 2 cm² in an otherwise well-preserved hip, where short-term symptom relief is relatively predictable. Once a defect reaches 2 cm² or larger, the early-failure rates associated with microfracture alone rise substantially — the clot stabilisation that AMIC provides becomes the more appropriate choice for lesions in this range.

Underlying cause matters alongside size. Both procedures are designed for focal, symptomatic full-thickness chondral defects arising from femoroacetabular impingement (FAI), labral pathology, direct trauma, or osteonecrosis. These are the scenarios where a defined lesion can be addressed surgically while the surrounding joint remains structurally sound enough to support repair.

Patient profile is equally important. Younger adults with focal defects and preserved joint space are the primary candidates for either technique. Neither approach is appropriate for diffuse hip osteoarthritis — widespread cartilage loss means there is no intact surrounding tissue to anchor a repair, and joint replacement becomes the correct pathway at that stage.

One further constraint applies where patients have undergone repeated microfracture in the same area: cumulative drilling can compromise the subchondral bone plate, potentially limiting the biological environment both procedures rely on. Imaging, typically MRI, helps a surgeon determine whether adequate bone stock remains before either approach is planned. Suitability is always a clinical judgement made case by case rather than a fixed rule.

What the procedure involves and what recovery looks like

AMIC in the hip is performed as a single arthroscopic session — no second procedure is required to harvest cells or reimplant them, which is the principal practical difference from two-stage approaches such as ACI or MACI. The operation follows the same foundational steps as standalone microfracture — the defect is prepared and the subchondral bone perforated to release marrow — with the additional step of cutting and securing the Chondro-Gide membrane precisely over the site, either glued or sutured into position. That additional step adds approximately 20 minutes of operative time and a scaffold consumable cost, but keeps the total procedure within a single day-case or short-stay admission.

The hip's constrained anatomy makes this technically demanding. Accurate membrane placement inside a deep, enclosed joint space requires specialist experience in hip arthroscopy; the same anatomical constraints that make clot stabilisation clinically valuable also make the procedure less forgiving than equivalent scaffold applications in other joints.

Post-operative recovery follows a closely similar protected pathway to standalone microfracture: typically six to eight weeks of non- or partial weight-bearing on crutches, giving the early repair tissue time to consolidate before load is progressively reintroduced. Full return to activity is gradual. The pace is guided by lesion size, the patient's response to rehabilitation, and — where indicated — follow-up imaging to assess repair quality before unrestricted loading resumes.

What the evidence shows and where gaps remain

The evidence base for AMIC in the hip carries a consistent pattern: strong mechanistic logic, encouraging clinical signals, and a recognised gap in hip-specific long-term RCT data.

The 2018 Bone & Joint systematic review by Hotham & Malviya — applying BMJ GRADE methodology across hip cartilage repair techniques — found that microfracture carries the largest volume of published evidence but also the most consistent long-term limitation. AMIC showed great promise, they concluded, particularly as a platform for coupling scaffold support with biological augmentation, though it warranted further research. Four years later, Kumar et al.'s 2022 PMC review of 35 studies found good short-to-medium-term results across single-stage biological techniques but noted that longer-term data for newer procedures, including AMIC, was still awaited.

The honest summary from both reviews is this: AMIC's short-to-medium-term outcomes are well supported, and reported durability extends to eight years in some series — with lower rates of conversion to total hip arthroplasty than microfracture alone — but a large, adequately powered hip-specific RCT with long-term follow-up has not yet been published.

A further gap worth naming directly: much of the comparative data in the broader cartilage repair literature derives from knee cohorts, where the biomechanical environment and defect geometry differ meaningfully from the hip. Extrapolation to the hip is mechanistically plausible — the scaffold biology is unchanged — but it is extrapolation nonetheless.

A registered trial (NCT05402072) is currently comparing AMIC with microfracture for hip cartilage repair using MRI-based outcome measures. When those results mature, they will indicate whether the durability advantage visible in registry and observational data holds under controlled conditions — which is precisely the question the field still needs answered.